AZN Astrazeneca PLC

44.31
+0.35  (+1%)
Previous Close 43.96
Open 44.02
Price To Book 8.86
Market Cap 116,289,401,212
Shares 2,624,450,490
Volume 5,735,201
Short Ratio 1.41
Av. Daily Volume 4,937,836
Stock charts supplied by TradingView

NewsSee all news

  1. RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca

    RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and Aemcolo® Movantik® generated U.S. net sales of

  2. BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

    BRILINTA monotherapy reduced bleeding complications with no increased risk of ischemic events in patients with diabetes undergoing percutaneous coronary intervention Consistent results were also observed in patients

  3. Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer

    SALT LAKE CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced it has submitted a supplementary application with the Japanese

  4. FARXIGA Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients With Chronic Kidney Disease

    FARXIGA is the first SGLT2 inhibitor to show meaningful benefit in patients with chronic kidney disease in a trial including both type-2 diabetics and non-diabetics The Dapagliflozin And Prevention of Adverse outcomes

  5. IMFINZI (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer

    Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit in combination with etoposide and a choice of carboplatin or cisplatin chemotherapy AstraZeneca today announced that IMFINZI® (durvalumab) has

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 poster at ESMO September 28, 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2020.
Tezepelumab - NAVIGATOR
Asthma
Expanded approval announced August 28, 2017.
Faslodex (fulvestrant)
Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer
PDUFA date December 20, 2020.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 trial stopped early due to overwhelming efficacy.
Farxiga (Dapa-CKD)
Chronic Kidney Disease
FDA Approval announced October 21, 2019.
Farxiga - DECLARE
Heart failure in patients with type-2 diabetes
Phase 2 data due in 2020.
MEDI0457
HPV-associated squamous cell carcinoma of the head & neck (SCCHN)
Phase 3 data released November 1, 2017 - primary endpoint not met.
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
PDUFA date under priority review 2Q 2020.
Farxiga (Dapa-HF)
Heart failure
Phase 3 data released May 30, 2018. Primary endpoint not met.
Benralizumab - TERRANOVA
COPD
Phase 3 data due 2021.
Roxadustat
Myelodysplastic syndromes (MDS)
Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 ongoing.
Brazikumab
Crohn's disease
Phase 3 data due 2021.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS1)
Severe, uncontrolled asthma
Phase 3 trial did not meet primary endpoint - noted July 26, 2018.
Selumetinib - ASTRA
Thyroid cancer
Phase 3 data released August 28, 2019. Primary endpoint met.
Breztri - (ETHOS)
Chronic obstructive pulmonary disease (COPD)
FDA approval announced September 13, 2018.
Moxetumomab
Cancer - leukaemia
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Approval announced August 17, 2017.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 data released July 27, 2017 - primary endpoint (PFS) not met. Overall survival data also did not meet primary endpoint - November 16, 2018.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data released August 21, 2019 did not meet primary endpoint.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data 1H 2020.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data released March 6, 2020 did not meet primary endpoint.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data released December 7, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data released April 24, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (ARCTIC)
Non-small cell lung cancer (NSCLC)
Approval announced February 19, 2018.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).
Bydureon
Type 2 Diabetes
Phase 3 data released February 25, 2019 met primary endpoint. Data presented at ESC Congress September 1, 2019 noted the treatment exhibited a reduction of cardiovascular (CV) death, heart attack, or stroke by 10% .
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 TULIP 1 data released August 31, 2018. Primary endpoint not met. TULIP 2 data released August 29, 2019 did meet primary endpoint.
Anifrolumab
Lupus
Priority Review announced August 2, 2017. Approval announced October 31, 2017.
Acalabrutinib
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
Urothelial carcinoma - Bladder cancer
Bladder cancer
Second CRL issued March 17, 2017. Approval announced May 18, 2018.
Lokelma (ZS-9)
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
Approval announced November 14, 2017.
Benralizumab
Severe, uncontrolled asthma
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
Phase 3 data met primary and secondary endpoints. ORR; 72.2% vs 51.4% for chemotherapy. PFS 13.4 months vs 9.2 months for chemo arm (HR 0.62).
Lynparza - SOLO 3
Third-line ovarian cancer
FDA Approval announced December 30, 2019.
Lynparza (POLO)
Pancreatic cancer
Phase 3 PFS data met primary endpoint. OS data due 2021.
Imfinzi + tremelimumab (POSEIDON)
Non-small cell lung cancer (NSCLC)
FDA approval announced March 30, 2020.
Imfinzi + tremelimumab (CASPIAN)
Small cell lung cancer (SCLC)
Phase 3 data due 2021.
Lynparza - OlympiA
HER2-negative breast cancer
Phase 3 trial did not meet primary endpoint - noted May 11, 2018.
Fasenra (benralizumab) - GALATHEA
Chronic obstructive pulmonary disease (COPD)
PDUFA date under priority review 2Q 2020.
Lynparza
Castration-Resistant Prostate Cancer
FDA Approval announced November 21, 2019.
Calquence
Chronic lymphocytic leukaemia
PDUFA date under priority review 2Q 2020.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 2/3 trial ongoing.
Brazikumab
Ulcerative colitis
Phase 1b/2 data likely due 2020.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 3 final OS data released August 9, 2019. Endpoint met. Presentation at ESMO September 2019 noted OS of 38.6 months versus 31.8 months for comparator arm; PFS HR 0.48.
Tagrisso - FLAURA
Non-small cell lung cancer (NSCLC)
Phase 3 trial met primary endpoint - January 27, 2020.
Brilinta (THALES)
Acute ischaemic stroke
Phase 3 trial to be discontinued due to low likelihood of demonstrating a benefit - January 13, 2020.
Epanova
Hypertriglyceridaemia CVOT
Phase 3 data due 2H 2020.
Fasenra
Nasal polyps
Phase 3 data due 2H 2020.
Imfinzi - AEGEAN
Neoadjuvant Non-small cell lung cancer (NSCLC)
Phase 2 trial met primary endpoint - noted April 4, 2019.
Fasenra
Hypereosinophilic Syndrome
Phase 3 data due 2021.
Trastuzumab deruxtecan - DESTINY-Breast04
HER low breast cancer
Phase 3 data due 2021.
Trastuzumab deruxtecan - DESTINY-Breast03
Second line HER2+ breast cancer
Phase 3 data due 2021.
Trastuzumab deruxtecan DESTINY-Breast02
Third line HER2+ breast cancer
FDA Approval announced December 20, 2019.
Enhertu (trastuzumab deruxtecan)
Third line HER2+ breast cancer
Phase 3 data due 2021+.
Fasenra
Asthma
Phase 3 data due 2021+.
Farxiga (Deliver)
Chronic Heart Failure (CHF), preserved ejection fraction (HFpEF)
Phase 3 positive interim data released May 7, 2019. Trial to be stopped early.
Calquence
Relapsed/refractory chronic lymphocytic leukaemia
FDA approval announced May 3, 2019.
Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride)
Type 2 diabetes
CRL issued for sNDA announced July 15, 2019.
Farxiga (Depict)
Type 1 diabetes
Phase 3 data due 2H 2020.
PT027
Asthma
Phase 3 data due 2H 2020.
Imfinzi - PACIFIC-2
Non-small cell lung cancer (NSCLC)
Phase 2 data trial met primary endpoint.
Trastuzumab deruxtecan - DESTINY-Gastric01
Gastric cancer
CRL announced October 1, 2019.
PT010
Chronic obstructive pulmonary disease (COPD)
Phase 3 trial did not meet primary endpoint - March 12, 2020.
Lynparza + cediranib
Ovarian cancer
Phase 3 data due 2021.
Imfinzi (PEARL)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2021+.
Imfinzi (PACIFIC-5)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2021.
Imfinzi + tremelimumab (NILE)
Bladder cancer
Phase 3 data due 2H 2020.
Imfinzi + tremelimumab - HIMALAYA
Hepatocellular carcinoma (HCC)
Phase 3 data due 2021.
Durvalumab - EMERALD-1
Locoregional Hepatocellular carcinoma (HCC)
Phase 3 data due 2021.
Durvalumab - ADRIATIC
Small cell lung cancer (SCLC) limited disease
Phase 3 data due 2021.
Lynparza - PROpel
Castration-resistant prostate cancer -first line

Latest News

  1. RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca

    RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and Aemcolo® Movantik® generated U.S. net sales of

  2. BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

    BRILINTA monotherapy reduced bleeding complications with no increased risk of ischemic events in patients with diabetes undergoing percutaneous coronary intervention Consistent results were also observed in patients

  3. Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer

    SALT LAKE CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced it has submitted a supplementary application with the Japanese

  4. FARXIGA Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients With Chronic Kidney Disease

    FARXIGA is the first SGLT2 inhibitor to show meaningful benefit in patients with chronic kidney disease in a trial including both type-2 diabetics and non-diabetics The Dapagliflozin And Prevention of Adverse outcomes

  5. IMFINZI (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer

    Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit in combination with etoposide and a choice of carboplatin or cisplatin chemotherapy AstraZeneca today announced that IMFINZI® (durvalumab) has

  6. FARXIGA reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

    New data showed consistent effect of FARXIGA in patients with heart failure with reduced ejection fraction, regardless of background therapy New data from a sub-analysis of the landmark Phase III DAPA-HF

  7. Moderna to Present at MIT Lecture Series

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that

  8. Lynparza granted orphan drug designation in Japan for BRCA-mutated metastatic pancreatic cancer

    AstraZeneca announced that Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer. Lynparza

  9. RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights

    Key Highlights: Talicia® approved by the FDA for the treatment of H. pylori infection in adults; U.S. launch with RedHill's sales force expected by mid-March 2020 Acquisition of global rights to Movantik® (naloxegol)

  10. Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study

    Phase 2 interim data at three months, expected in 3Q 2020, intended to inform Phase 3 dose selection Pivotal Phase 3 study manufacturing and planning underway; study start expected in 2021 CMV is the most common

  11. Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced updated

  12. Moderna to Host Manufacturing & Digital Day on March 4, 2020

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it

  13. Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities

    Two of three dose cohorts in Phase 2 CMV vaccine (mRNA-1647) dose-confirmation study completed enrollment; third and final cohort rapidly enrolling Up to $2 billion to invest, including cash and investments, financing

  14. RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca

    RedHill to promote Movantik® in the U.S. upon closing Movantik® generated U.S. net sales of $96 million in 2019Acquisition financing to be provided by HealthCare Royalty Partners (HCR) as part of the $115 million

  15. Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study

    mRNA-1273 delivered from Company's cGMP facility in 42 days from sequence selection Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to

  16. Moderna to Present at Upcoming Investor Conferences

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its

  17. NeoTX Closes $45 Million Series C Financing

    REHOVOT, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted anticancer

  18. Moderna to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26th, 2020

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it

  19. Moderna Announces Pricing of Public Offering of Shares of Common Stock

    Moderna, Inc. (NASDAQ:MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the

  20. FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease

    SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review of its New Drug Application (NDA) for

  21. Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer

    SALT LAKE CITY, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA)

  22. Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates

    Phase 2 CMV vaccine dose-confirmation study more than sixty percent enrolled mRNA-1189 to prevent infectious mononucleosis and Epstein-Barr virus (EBV) infection mRNA-1345 to prevent respiratory syncytial virus

  23. Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia

    mRNA-3704 is Moderna's first rare disease program to enter clinical studies Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new

  24. Moderna Announces Proposed Public Offering of Shares of Common Stock

    Moderna, Inc. (NASDAQ:MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it

  25. Deutsche Bank Appointed as Successor Depositary Bank for the NYSE-Listed American Depositary Receipt Program of AstraZeneca PLC

    Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt Program of AstraZeneca PLC (NYSE:AZN). AstraZeneca is a global, science-led biopharmaceutical

  26. Educational Lung Cancer Event Coming to The Villages to Raise Awareness of the State's High Rate of Lung Cancer

    Florida has a rate of 59.3 per 100,000 new lung cancer cases compared to the national rate of 59.6. In an effort to show how advances in science are being harnessed in the fight against lung cancer, The LungXperience,

  27. Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that

  28. BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke

    BRILINTA reduced the risk of the composite of stroke and death after an acute ischemic stroke or transient ischemic attack High-level results from the Phase III THALES trial showed AstraZeneca's BRILINTA (ticagrelor)

  29. Brilinta met primary endpoint in Phase III THALES trial in stroke

    High-level results from the Phase III THALES trial showed AstraZeneca's Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful

  30. AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

    NORTH CHICAGO, Ill. and DUBLIN, Jan. 27, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE:AGN), a leading global pharmaceutical company, today announced that

  31. Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

    Collaboration includes the National Institutes of Health (NIH) and leverages flexibility of Moderna's mRNA vaccine technology Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA

  32. Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer

    SALT LAKE CITY, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval

  33. Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

    mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases mRNA-6981 encodes PD-L1 to treat autoimmune disease, initially to be

  34. Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma

    Agreement enabled by Veracyte acquisition of NanoString diagnostics assets for global expansion Veracyte (NASDAQ:VCYT) today announced a multi-year partnership with Acerta Pharma, the hematology research and

  35. Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction

    AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular

  36. FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction

    AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for FARXIGA® (dapagliflozin) to reduce the risk of cardiovascular

  37. Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer

    AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatment of adult

  38. Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer

    SALT LAKE CITY, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has

  39. LYNPARZA (Olaparib) Approved in the US as a 1st-line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Cancer

    LYNPARZA reduced the risk of disease progression or death by 47% in patients whose disease had not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen  Only PARP inhibitor approved in

  40. Starpharma: Commencement of Phase 1 Trial for AZD0466 Utilising DEP® Delivery Technology

    AstraZeneca has commenced its first-in-human/phase 1 clinical trial for AZD0466 in the US in a range of cancers AZD0466 utilises Starpharma's proprietary DEP® delivery technology and is a highly optimised

  41. ENHERTU (fam-trastuzumab deruxtecan-nxki) Approved in the US for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens

    Accelerated Approval of AstraZeneca and Daiichi Sankyo's ENHERTU based on the DESTINY-Breast01 trial that showed clinically meaningful and durable responses AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi

  42. SK Holdings strengthens partnership with AstraZeneca, a global bio-pharmaceutical company

    SEOUL, South Korea, Dec. 19, 2019 /PRNewswire/ -- SK Holdings, which views bio-pharmaceutical businesses as a future growth driver, is strengthening partnership with global pharmaceutical companies. SK Holdings CEO,

  43. Moderna Announces Key 2020 Investor and Analyst Events

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its key

  44. [Fam]-Trastuzumab Deruxtecan Achieved a Tumor Response of 60.9% in Pivotal Phase II HER2-positive Metastatic Breast Cancer Trial

    AstraZeneca and Daiichi Sankyo's [fam]-trastuzumab deruxtecan demonstrated an impressive 14.8-month median duration of response and 16.4-month median progression-free survival AstraZeneca and Daiichi Sankyo Company,

  45. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  46. CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia

    Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at 24

  47. CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia

    Two Phase III CALQUENCE trials demonstrated superior progression-free survival across multiple settings while maintaining favorable tolerability CALQUENCE combined with obinutuzumab and as monotherapy reduced the risk

  48. Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Who Underwent PCI Showed BRILINTA Monotherapy Reduced the Risk of Clinically Relevant Bleeding Compared With Dual Antiplatelet Therapy (DAPT)

     Secondary endpoint of subgroup analysis showed similar rates of the composite of all-cause death, myocardial infarction or stroke between monotherapy and DAPT Results of subgroup analysis of TWILIGHT randomized

  49. Consistent Effects of FARXIGA in Heart Failure Patients With Reduced Ejection Fraction Shown in New Analyses From Landmark Phase III DAPA-HF Trial

    Data were consistent in patients with and without type 2 diabetes, showed early effects in the first month and improvement in patient-reported outcomes AstraZeneca today announced new data from five additional

  50. AstraZeneca Launches Diabetes Can Break Your Heart

     Announced on World Diabetes Day, the national movement will travel across America in 2020 to educate and activate communities around the connection between type 2 diabetes and heart failure AstraZeneca today announced

  51. Innate Pharma third quarter 2019 report

    Cash, cash equivalents and financial assets of the Company amounted to €215.2 millioni $79.1 million (€71.4 millionii) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to advance to

  52. Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer

    HOUSTON and WILMINGTON, Del., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV) and AstraZeneca (NYSE:AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of AVB-500, a GAS6/AXL

  53. Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators

    In non dialysis-dependent patients receiving roxadustat, the risk of MACE, MACE+ and all-cause mortality was comparable to placebo Dialysis-dependent patients receiving roxadustat had a lower risk of MACE+ and no

  54. New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced the Worsening of Heart Failure or Cardiovascular Death in HFrEF Patients With and Without Chronic Kidney Disease

    AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® (dapagliflozin) for the treatment of heart failure (HF). The data showed that FARXIGA on top of

  55. Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials

    OLYMPUS demonstrated a mean increase of 1.75g/dL averaged over weeks 28 to 52, compared to 0.40g/dL with placebo ROCKIES demonstrated a mean increase of 0.77g/dL averaged over weeks 28 to 52, compared to 0.68g/dL with

  56. CALQUENCE® Data To Show Improved Progression-Free Survival In Phase III Front-Line Chronic Lymphocytic Leukemia At ASH 2019 Annual Meeting

    Robust early-stage pipeline advancements and presentations across multiple scientific platforms demonstrate potential to improve treatment outcomes in blood cancers with high unmet need AstraZeneca will present the

  57. Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

    SHANGHAI and LONDON, Nov. 6, 2019 /PRNewswire/ -- Antengene Corporation today announced that it has entered into a licensing agreement with AstraZeneca (NYSE:AZN) under which Antengene has been granted the exclusive

  58. AstraZeneca to Present Pivotal Roxadustat Phase III Data at the American Society of Nephrology Kidney Week 2019

    Pooled efficacy and cardiovascular safety analyses from global Phase III program, and efficacy data from Phase III OLYMPUS and ROCKIES trials to be presented Unprecedented 41 abstracts from the AstraZeneca renal

  59. IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line Treatment of Stage IV Non-Small Cell Lung Cancer

    POSEIDON included both non-squamous and squamous patients and a broad choice of standard chemotherapy options AstraZeneca today announced positive progression-free survival (PFS) results for IMFINZI and tremelimumab,

  60. ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology

    LOS ANGELES, Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (NYSE:AZN),

  61. AstraZeneca Launches Signature STEM Program to Empower Students to Live Healthier Lives and Inspire Future Scientists

    ‘Generation Health: How Science Powers Us' is a dynamic program designed to make the connection between students' health and the science behind the prevention and treatment of diseases AstraZeneca today announced the

  62. FASENRA® (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen™

    FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor's office with eight-week maintenance dosing AstraZeneca today announced that the US Food and Drug

  63. Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress

    IPH5401 dose-escalation study in combination with durvalumab in advanced solid tumors, STELLAR-001, shows manageable safety profile Initiation of two expansion cohorts in non-small cell lung cancer (NSCLC) with

  64. LYNPARZA (olaparib) More Than Doubled the Time Without Radiographic Disease Progression in Patients With BRCA1/2- or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

    AstraZeneca and Merck's LYNPARZA reduced the risk of disease progression or death by 51% in men with homologous recombination repair (HRR) gene mutations First positive Phase III trial testing a targeted treatment in

  65. TAGRISSO Is the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years

    28% of patients in the global FLAURA trial were still receiving TAGRISSO at three years vs. 9% on either gefitinib or erlotinib TAGRISSO showed a 52% reduction in risk of central nervous system disease progression or

  66. LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer

    AstraZeneca and Merck's LYNPARZA added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as

  67. BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial

    Secondary endpoint of non-inferiority achieved for the risk of composite of MI, death or stroke Results presented at TCT 2019 conference and published in the New England Journal of Medicine New data from TWILIGHT, a

  68. Monalizumab to advance to Phase III in head and neck cancer

    Marseille, France, September 26, 2019, 7:00 AM CEST Innate Pharma SA (the "Company" or "Innate" - Euronext Paris: FR0010331421 – IPH), today announced that AstraZeneca (NYSE:AZN) will advance monalizumab into a Phase

  69. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NetworkNewsWire Editorial Coverage: Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX Profile)

  70. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Advances in biotechnology look to deliver promising new treatment options against breast cancer.  Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX

  71. Biotech Companies Endeavor to Address Global Health Issues

    NEW YORK, Sept. 18, 2019 /PRNewswire/ -- The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report

  72. FDA Grants Fast Track Designation for FARXIGA in Heart Failure

    AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the

  73. IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer

    In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone AstraZeneca today presented detailed results from the Phase III CASPIAN

  74. Theragnostics Signs Agreement with AstraZeneca

    LONDON, Sept. 5, 2019 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces a licence agreement with AstraZeneca (NYSE:AZN) for

  75. BRILINTA Reduced the Risk of Cardiovascular Events in Patients With Coronary Artery Disease and Type 2 Diabetes in Phase III THEMIS Trial

    AstraZeneca today announced detailed results from the positive Phase III THEMIS trial, which showed BRILINTA (ticagrelor) plus aspirin reduced the relative risk for the composite of cardiovascular (CV) death, heart

  76. Detailed Results from Phase III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both the Incidence of Cardiovascular Death and the Worsening of Heart Failure

    DAPA-HF is the first outcomes trial with an SGLT2 inhibitor in patients with heart failure with reduced ejection fraction, with and without type 2 diabetes AstraZeneca today announced detailed results from the landmark

  77. PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease

    At both standard and low budesonide doses, the triple-combination therapy showed a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies First

  78. PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease

    At both standard and low budesonide doses, the triple-combination therapy showed a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies First

  79. FDA Grants Fast Track Designation for FARXIGA in Chronic Kidney Disease

    AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to delay the progression of renal failure and prevent